StockWatch
·

Concord Drugs Ltd Q4 FY25 Results

CONCORDQ4 FY25 Results
Filing
MetricValue ( Cr)vs Q3 FY25
Revenue10.393.8%
Total Income10.403.7%
Expenditure10.340.6%
PBT0.0689.0%
Net Profit0.0482.8%
OPM10.03%13.18pp
NPM0.38%1.72pp
EPS0.0482.6%
View full financials

Informational and educational content only. Not investment advice.